期刊文献+

代谢综合征患者血清C反应蛋白水平的研究及吡格列酮的干预作用

下载PDF
导出
摘要 目的研究代谢综合征患者超敏C反应蛋白(hs-CRP)的变化对病情、预后的价值。方法研究组和正常对照组各40例,治疗前进行各项指标的比较,包括BMI、SBP、DBP、TC、TG、HDL-C、FBG、FINS、HBA1c、hs-CRP、IR、ISI等,然后将研究组采用吡格列酮干预,治疗并观察以上各项指标的变化。结果治疗前与正常对照组比较,研究组hs-CRP、FINS明显升高,BMI、SBP、DBP、TC、TG、FPG、HBA1c、IR均有升高,HDL-C、ISI明显下降,差异均有显著性意义(P<0·01或<0·05);研究组治疗前后比较,hs-CRP、FINS明显下降,SPB、TG、FPG、HBA1c、IR均有降低,HDL-C、ISI上升,差异有显著性意义(P<0·01或<0·05),BMI、DBP、TC间差异均无显著性意义(P>0·05)。结论吡格列酮可提高胰岛素敏感性,降低胰岛素抵抗,改善β细胞功能,降低血糖、血压,升高HDL-C,降低TG,可抑制慢性炎症反应,降低hs-CRP,改善内皮细胞功能,进而全面的控制动脉粥样硬化,高血压,冠心病,糖尿病的发生发展,且服药方便,作用时间长,耐受性好,副作用小,为治疗代谢综合征安全有效的药物。
作者 陆君
出处 《实用心脑肺血管病杂志》 2006年第6期461-462,共2页 Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
  • 相关文献

参考文献6

  • 1Execuive Summary of The Third Report of The National Cholesterol Education Program(NCEP) Expert Panel on Detection,Evaluation,And Treatment of High Blood Cholesterol In Adults(Adult Treatment Panel Ⅲ)[J].JAMA,2001,285(19):2486-2497.
  • 2Pasceri V,Willerson JT,Yeh ET.Direct proinflammatory effect of C-reactive protein on human endothelial cells[J].Circulation,2002,102:2165-2167.
  • 3李晨钟,薛耀明,高方,汪敏.高尿酸血症患者血清超灵敏C反应蛋白水平与胰岛素抵抗[J].中国全科医学,2006,9(6):451-452. 被引量:6
  • 4Pradhan AD,manson JE,Rifai N,et al.C-reactive protein,in terlenlcin 6,and the risk of developing type 2 diabetes mellitus[J].JAMA,2001,286:327-334.
  • 5Festa AD,Agostino R Jr,Howard G,et al.Chronic subclinical inflammation as part of the insulin resistance spndrome.The Insulin Resistance Atherosclerosis study(IRAS)[J].Circulation,2000,102(1):42-47.
  • 6潘长玉,高妍,高鑫,李光伟,罗邦尧,史虹莉,田慧,贾培红,林寰东,邢小燕,赵咏桔,周丽诺.盐酸吡格列酮治疗2型糖尿病的有效性和安全性的多中心临床研究[J].中华内科杂志,2002,41(6):388-392. 被引量:26

二级参考文献18

  • 1Izumi I, Hosiyama K, Enomoto S, et al. Pharmacokinetics of troglitazone, an antidiabetic agent: prediction of in vivo stereoselective sulfation and glucuronidation from in vitro data. J Pharmacol Exp Ther, 1997, 280:1392-1400.
  • 2Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med, 2001, 111 :10-17.
  • 3Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care , 2000, 23: 1605-1611.
  • 4Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther, 2000 , 22: 1395-1409.
  • 5Rubin C, Egan J, Schneider R. Combination therapy with pioglitazone and insulin in patients with type 2 diabetes. Diabetes,1999 , 48 Suppl 1:A110.
  • 6Kelly IE, Han TS, Walsh K, et al. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care, 1999, 22:288-293.
  • 7Gillies PS, Dunn CJ. Pioglitazone. Drugs, 2000, 60:333-343.
  • 8Hanefeld M. The metabolic syndrome: roots, myths and facts. In: Hanefeld M, Leonhardt W.eds. The metabolic syndrome. Jena: Gustav Fischer, 1997. 13-24.
  • 9Groop LC. Insulin resistance: the fundamental trigger of type 2 diabetes. Diabetes Obes Metab, 1999, 1 Suppl 1:S1-7.
  • 10Beck-Nielsen H, Groop LC. Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin-dependent diabetes mellitus. J Clin Invest, 1994, 94:1714-1721.

共引文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部